(Q33785424)

29 July 2017

1 reference

title

Epirubicin: a review of its intravesical use in superficial bladder cancer (English)

1 reference

29 July 2017

S V Onrust

1

1 reference

29 July 2017

L R Wiseman

series ordinal

2

1 reference

29 July 2017

K L Goa

series ordinal

3

1 reference

29 July 2017

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

15

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

307-333

1 reference

Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group

29 July 2017

cites work

1 reference

12 December 2020

Immunotherapy of bladder cancer

1 reference

12 December 2020

Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder

1 reference

12 December 2020

Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

1 reference

12 December 2020

Superficial bladder cancer: progression and recurrence

1 reference

12 December 2020

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

1 reference

12 December 2020

Initial evaluation and response criteria for patients with superficial bladder cancer. Report of a workshop

1 reference

12 December 2020

Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin

1 reference

12 December 2020

Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

1 reference

12 December 2020

Appropriate endpoints for superficial bladder cancer clinical trials

1 reference

12 December 2020

Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III

1 reference

12 December 2020

Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer

1 reference

12 December 2020

Superficial bladder cancer: Diagnosis, surveillance and treatment

1 reference

12 December 2020

Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study

1 reference

12 December 2020

An overview of intravesical therapy for superficial bladder tumors

1 reference

12 December 2020

Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study

1 reference

12 December 2020

Multidrug resistance evaluation by confocal microscopy in primary urothelial cancer explant colonies

1 reference

12 December 2020

Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor--prophylactic and therapeutic instillation for carcinoma in situ

1 reference

12 December 2020

A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group

1 reference

12 December 2020

A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group

1 reference

12 December 2020

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin

1 reference

12 December 2020

Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder

1 reference

12 December 2020

Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group

1 reference

12 December 2020

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction

1 reference

12 December 2020

Clinical pharmacokinetics of epirubicin.

1 reference

12 December 2020

A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group

1 reference

12 December 2020

Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors

1 reference

12 December 2020

4'-Epidoxorubicin versus Mitomycin C Intravesical Chemoprophylaxis of Superficial Bladder Cancer

1 reference

12 December 2020

Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

1 reference

12 December 2020

BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.

1 reference

12 December 2020

P glycoprotein (P-gp) and drug resistance--time for reappraisal?

1 reference

12 December 2020

Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.

1 reference

12 December 2020

The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.

1 reference

12 December 2020

Intravesical epirubicin in the prophylaxis of superficial bladder cancer

1 reference

12 December 2020

BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes

1 reference

12 December 2020

Therapy of superficial bladder cancer.

1 reference

12 December 2020

Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy

1 reference

12 December 2020

[Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI]

1 reference

12 December 2020

Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin

1 reference

12 December 2020

Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.

1 reference

12 December 2020

Principles of intravesical chemotherapy and immunotherapy

1 reference

12 December 2020

Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group

1 reference

12 December 2020

Intravesical chemotherapy with epirubicin: a dose response study

1 reference

12 December 2020

[Intravesical chemotherapy with 4'-EPI-adriamycin in patients with superficial bladder tumors (randomized study)]

1 reference

12 December 2020

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

1 reference

12 December 2020

A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.

1 reference

12 December 2020

Cellular and molecular pharmacology of 4'-epidoxorubicin in HeLa cells. Comparison with its parent drug, doxorubicin

1 reference

12 December 2020

The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report

1 reference

12 December 2020

A pilot study comparing different dose levels and administration schedules of interferon-α2b combined with epirubicin for prevention of recurrence in bladder cancer

1 reference

12 December 2020

Maximum utilization of the life table method in analyzing survival

1 reference

12 December 2020

Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder

1 reference

12 December 2020

Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors

1 reference

12 December 2020

Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.

1 reference

12 December 2020

Trial with bacillus Calmette-Guérin and epirubicin combination in the prophylaxis of superficial bladder cancer

1 reference

12 December 2020

A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin

1 reference

12 December 2020

Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells

1 reference

12 December 2020

Diagnosis and treatment of superficial transitional cell carcinoma of the bladder: facts and perspectives.

1 reference

12 December 2020

Carcinoma in situ of the bladder

1 reference

12 December 2020

Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model

1 reference

12 December 2020

Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours

1 reference

12 December 2020

Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer

1 reference

12 December 2020

Drugs ten years later: epirubicin.

1 reference

12 December 2020

Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder

1 reference

12 December 2020

Current recommendations for the management of bladder cancer. Drug therapy

1 reference

12 December 2020

Intravesical Instillations of 4-EPI-Doxorubicin (Epirubicin) in the Prophylactic Treatment of Superficial Bladder Cancer: Results of a Controlled Prospective Study

1 reference

12 December 2020

A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment

1 reference

12 December 2020

Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder.

1 reference

12 December 2020

Treatment of superficial bladder cancer with intravesical chemotherapy

1 reference

12 December 2020

Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours

1 reference

12 December 2020

A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour

1 reference

12 December 2020

10.2165/00002512-199915040-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1020061456

0 references

1 reference